Secukinumab
Brand Names: Cosentyx
Methodology & AI Transparency ⓘ
Secukinumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Listed in the U.S.
- 2 Real-world patient consensus: Zero-PHI community consensus: 79% favorable across 5 logged regimens (Cosentyx).
- 3 Typical cash cost range: 30-day cash pricing ranges from $185.00 discount cash to $453.25 walk-in retail (NADAC $3692.3110/unit).
- 4 Top reported side effects / signs: Most commonly reported Secukinumab tolerability events: nausea (9.3%), headache (8.6%), dizziness (5.8%).
Ask our AI Specialists anything about Secukinumab
Secukinumab Mechanism, CYP450 Pathways & DailyMed Monograph
Listed in the U.S. FDA National Drug Code Registry (0078-0639, 0078-1070), Secukinumab serves as a subcutaneous-route prescription interleukin-17a antagonist (150 mg/mL Injection and 300 mg/2mL Injection, manufactured/labeled by Novartis Pharmaceuticals Corporation) utilized in evidence-based specialty and primary care protocols.
Upon subcutaneous-route administration of 150 mg/mL Injection and 300 mg/2mL Injection, Secukinumab (manufactured/labeled by Novartis Pharmaceuticals Corporation; NDC 0078-0639, 0078-1070) engages interleukin-17a antagonist biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination.
Pharmacokinetic profiling of Secukinumab demonstrates an elimination half-life of Elimination kinetics span 11 to 19 hours per Secukinumab clinical pharmacology with Complete (~100%) parenteral systemic delivery for Secukinumab (150 mg/mL Injection) systemic bioavailability; clearance proceeds via systemic clearance of secukinumab integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after secukinumab administration.
Titration schedules for Secukinumab (150 mg/mL Injection → 300 mg/2mL Injection → 25 mg/mL Injection, Solution, Concentrate → 75 mg/.5mL Injection) require excluding contraindicated in patients with prior serious allergic response to secukinumab (ndc 0078-0639); severe baseline organ impairment where secukinumab accumulation exceeds safe therapeutic margins; real-world patient logs highlight nausea (9.3% of reports), headache (8.6% of reports), fatigue (5.8% of reports) alongside a 79.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Secukinumab in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Secukinumab dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Secukinumab (NDC 0078-0639)
- Severe baseline organ impairment where Secukinumab accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (5 Reports)
Secukinumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Secukinumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in: What a 1,427-Participant Study Found Clinical efficacy of secukinumab vs. Arthritis research & therapy • 2026-04-11 • Phase III Randomized Trial | N = 1,427 | 96/100 | PMID 41965705 ↗ |
| New Insights on Secukinumab improves physical function and quality of life and inhibits: What a 996-Participant Study Found Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression. RMD open • 2023-04-15 • Phase III Randomized Trial | N = 996 | 93/100 | PMID 37094983 ↗ |
| New Insights on Benefits and safety of Intravenous Secukinumab in Patients With Active Axial: What a 264-Participant Study Found IV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2025-02-15 • Phase III Randomized Trial | N = 264 | 93/100 | PMID 39300513 ↗ |
| New Insights on Secukinumab maintains superiority over ustekinumab in clearing skin and improving: What a 550-Participant Study Found This second head-to-head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-01-15 • Phase III Randomized Trial | N = 550 | 93/100 | PMID 32365251 ↗ |
| New Insights on Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in: What a 555-Participant Study Found Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-01-15 • Phase III Randomized Trial | N = 555 | 93/100 | PMID 32770640 ↗ |
Secukinumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3692.3110/unit (~$110769.33/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
| Hone Health Hormone & At-Home Biomarker Lab (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00 consult | Program details |
| Midi Health Perimenopause & HRT Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $59.00 consult | Program details |
Secukinumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Secukinumab RxNorm Concept ID | RXN-00780639-2623 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3692.3110 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 79.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Secukinumab Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Secukinumab integrating DailyMed SPL (2026-07-01), CMS NADAC ($3692.3110/unit), and 5 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Secukinumab community threads and patient logs by age, biological sex, dosage, and treatment duration.